Skip to main content

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

*October 2021*


  • Acquired resistance mechanisms to osimertinib can be EGFR dependent or independent.
  • First- and fourth-generation EGFR-TKIs are able to overcome EGFR-dependent resistance.
  • MET and MEK inhibitors may overcome EGFR-independent resistance.
  • Anti-HER/MET novel monoclonal antibody seems effective across multiple resistance mechanisms.
  • Carboplatin/paclitaxel ± bevacizumab/atezolizumab represents a feasible option in ‘fit’ patients progressing on osimertinib.